Interleukin 21 – its potential role in the therapy of B-cell lymphomas

References

• Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57–63.
   PubMed Web of Science ®Google Scholar
• Ozaki K, Kikly K, Michalovich D, et al. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA. 2000;97:11439–11444.
   PubMed Web of Science ®Google Scholar
• Chtanova T, Tangye SG, Newton R, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol. 2004;173:68–78.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448:484–487.
   PubMed Web of Science ®Google Scholar
• Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448:480–483.
   PubMed Web of Science ®Google Scholar
• Wurster AL, Rodgers VL, Satoskar AR, et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med. 2002;196:969–977.
   PubMed Web of Science ®Google Scholar
• Ettinger R, Sims GP, Fairhurst AM, et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol. 2005;175:7867–7879.
   PubMed Web of Science ®Google Scholar
• Brady J, Hayakawa Y, Smyth MJ, et al. IL-21 induces the functional maturation of murine NK cells. J Immunol. 2004;172:2048–2058.
   PubMed Web of Science ®Google Scholar
• Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol. 2005;5:688–698.
   PubMed Web of Science ®Google Scholar
• Mehta DS, Wurster AL, Grusby MJ. Biology of IL-21 and the IL-21 receptor. Immunol Rev. 2004;202:84–95.
   PubMed Web of Science ®Google Scholar
• Habib T, Senadheera S, Weinberg K, et al. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry. 2002;41:8725–8731.
   PubMed Web of Science ®Google Scholar
• Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol. 2001;167:1–5.
   PubMed Web of Science ®Google Scholar
• Konforte D, Paige CJ. Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J Immunol. 2006;177:8381–8392.
   PubMed Web of Science ®Google Scholar
• Zeng R, Spolski R, Casas E, et al. The molecular basis of IL-21-mediated proliferation. Blood. 2007;109:4135–4142.
   PubMed Web of Science ®Google Scholar
• Brenne AT, Ro TB, Waage A, et al. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood. 2002;99:3756–3762.
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Foster DC, Holly RD, et al. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol. 2002;72:856–863.
   PubMed Web of Science ®Google Scholar
• Suto A, Nakajima H, Hirose K, et al. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood. 2002;100:4565–4573.
   PubMed Web of Science ®Google Scholar
• Strengell M, Sareneva T, Foster D, et al. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol. 2002;169:3600–3605.
   PubMed Web of Science ®Google Scholar
• Zeng R, Spolski R, Finkelstein SE, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med. 2005;201:139–148.
   PubMed Web of Science ®Google Scholar
• Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005;175:2261–2269.
   PubMed Web of Science ®Google Scholar
• Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol. 2007;178:732–739.
   PubMed Web of Science ®Google Scholar
• He H, Wisner P, Yang G, et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med. 2006;4:24.
   PubMed Web of Science ®Google Scholar
• Wang G, Tschoi M, Spolski R, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 2003;63:9016–9022.
   PubMed Web of Science ®Google Scholar
• Roda JM, Parihar R, Lehman A, III, et al. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol. 2006;177:120–129.
   PubMed Web of Science ®Google Scholar
• Simona Sivori CC, Parolini S, Marcenaro E, et al. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol. 2003;33:3439–3447.
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest. 2004;114:1379–1388.
   PubMed Web of Science ®Google Scholar
• Strengell M, Matikainen S, Siren J, et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol. 2003;170:5464–5469.
   PubMed Web of Science ®Google Scholar
• Coquet JM, Kyparissoudis K, Pellicci DG, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol. 2007;178:2827–2834.
   PubMed Web of Science ®Google Scholar
• Arguni E, Arima M, Tsuruoka N, et al. JunD/AP-1 and STAT3 are the major enhancer molecules for high Bcl6 expression in germinal center B cells. Int Immunol. 2006;18:1079–1089.
   PubMed Web of Science ®Google Scholar
• Brandt K, Singh PB, Bulfone-Paus S, et al. Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev. 2007;18:223–232.
   PubMed Web of Science ®Google Scholar
• Ozaki K, Spolski R, Ettinger R, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol. 2004;173:5361–5371.
   PubMed Web of Science ®Google Scholar
• Mehta DS, Wurster AL, Whitters MJ, et al. IL-21 induces the apoptosis of resting and activated primary B cells. J Immunol. 2003;170:4111–4118.
   PubMed Web of Science ®Google Scholar
• Jin H, Carrio R, Yu A, et al. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol. 2004;173:657–665.
   PubMed Web of Science ®Google Scholar
• Herrin BR, Justement LB. Expression of the adaptor protein hematopoietic Src homology 2 is up-regulated in response to stimuli that promote survival and differentiation of B cells. J Immunol. 2006;176:4163–4172.
   PubMed Web of Science ®Google Scholar
• Saito T, Kitayama D, Sakamoto A, et al. Effective collaboration between IL-4 and IL-21 on B cell activation. Immunobiology. 2008;213:545–555.
   PubMed Web of Science ®Google Scholar
• Ettinger R, Sims GP, Robbins R, et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol. 2007;178:2872–2882.
   PubMed Web of Science ®Google Scholar
• Skak K, Kragh M, Hausman D, et al. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov. 2008;7:231–240.
   PubMed Web of Science ®Google Scholar
• Leonard WJ, Wan CK. IL-21 Signaling in Immunity. F1000Res 2016;5.
   PubMedGoogle Scholar
• Ugai S, Shimozato O, Yu L, et al. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther. 2003;10:771–778.
   PubMed Web of Science ®Google Scholar
• Ugai S, Shimozato O, Kawamura K, et al. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther. 2003;10:187–192.
   PubMed Web of Science ®Google Scholar
• Di Carlo E, Comes A, Orengo AM, et al. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol. 2004;172:1540–1547.
   PubMed Web of Science ®Google Scholar
• Daga A, Orengo AM, Gangemi RM, et al. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer. 2007;121:1756–1763.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Matthews J, Parvin S, et al. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood. 2015;126:1555–1564.
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635–2642.
   PubMed Web of Science ®Google Scholar
• Roda JM, Joshi T, Butchar JP, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res. 2007;13:6419–6428.
   PubMed Web of Science ®Google Scholar
• Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004;10:2253–2264.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Byrd JC, Andorsky DJ, et al. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res. 2012;18:5752–5760.
   PubMed Web of Science ®Google Scholar
• Krejsa CM, Holly RD, Heipel M, et al. Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models. PLoS One. 2013;8:e67256.
   PubMed Web of Science ®Google Scholar
• Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6:34–55.
   PubMed Web of Science ®Google Scholar
• Young PA, Morrison SL, Timmerman JM. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin Oncol. 2014;41:623–636.
   PubMed Web of Science ®Google Scholar
• Williams P, Rafei M, Bouchentouf M, et al. A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol Ther. 2010;18:1293–1301.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Jiang X, Shing SU, et al. Targeting B-cell malignancies with anti-CD20-interleukin-21 fusokine. Blood. 2013;122:377 (abstract).
   Web of Science ®Google Scholar
• de Totero D, Meazza R, Zupo S, et al. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood. 2006;107:3708–3715.
   PubMed Web of Science ®Google Scholar
• de Totero D, Meazza R, Capaia M, et al. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood. 2008;111:517–524.
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Wooldridge JE, Blackwell SE, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol. 2005;77:378–387.
   PubMed Web of Science ®Google Scholar
• Gowda A, Roda J, Hussain SR, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 2008;111:4723–4730.
   PubMed Web of Science ®Google Scholar
• Sarosiek KA, Malumbres R, Nechushtan H, et al. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood. 2010;115:570–580.
   PubMed Web of Science ®Google Scholar
• Wu L, Ehlin-Henriksson B, Zhu H, et al. EBV counteracts IL-21-induced apoptosis in an EBV-positive diffuse large B-cell lymphoma cell line. Int J Cancer. 2013;133:766–770.
   PubMed Web of Science ®Google Scholar
• Gelebart P, Zak Z, Anand M, et al. Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia. 2009;23:1836–1846.
   PubMed Web of Science ®Google Scholar
• Akamatsu N, Yamada Y, Hasegawa H, et al. High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. Cancer Lett. 2007;256:196–206.
   PubMed Web of Science ®Google Scholar
• de Totero D, Capaia M, Fabbi M, et al. Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. Exp Hematol. 2010;38:373–383.
   PubMed Web of Science ®Google Scholar
• Wood B, Sikdar S, Choi SJ, et al. Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease. Leuk Lymphoma. 2013;54:1212–1220.
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16:637–650.
   PubMed Web of Science ®Google Scholar
• Ueda M, Imada K, Imura A, et al. Expression of functional interleukin-21 receptor on adult T-cell leukaemia cells. Br J Haematol. 2005;128:169–176.
   PubMed Web of Science ®Google Scholar
• Dien Bard J, Gelebart P, Anand M, et al. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol. 2009;175:825–834.
   PubMed Web of Science ®Google Scholar
• Menoret E, Maiga S, Descamps G, et al. IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. J Immunol. 2008;181:6837–6842.
   PubMed Web of Science ®Google Scholar
• Scheeren FA, Diehl SA, Smit LA, et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood. 2008;111:4706–4715.
   PubMed Web of Science ®Google Scholar
• Hashmi MH, Van Veldhuizen PJ. Interleukin-21: updated review of phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther. 2010;10:807–817.
   PubMed Web of Science ®Google Scholar
• Davis ID, Brady B, Kefford RF, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 2009;15:2123–2129.
   PubMed Web of Science ®Google Scholar
• Davis ID, Skrumsager BK, Cebon J, et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res. 2007;13:3630–3636.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Curti BD, Redman BG, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol. 2008;26:2034–2039.
   PubMed Web of Science ®Google Scholar
• Schmidt H, Brown J, Mouritzen U, et al. Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. Clin Cancer Res. 2010;16:5312–5319.
   PubMed Web of Science ®Google Scholar
• Dodds MG, Frederiksen KS, Skak K, et al. Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. Cancer Immunol Immunother. 2009;58:843–854.
   PubMed Web of Science ®Google Scholar
• Petrella TM, Tozer R, Belanger K, et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol. 2012;30:3396–3401.
   PubMed Web of Science ®Google Scholar
• Petrella TM, M C, McWhirter E, et al. Final efficacy results of NCIC CTG IND.202: a randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM). J Clin Oncol. 2013;31.
   Google Scholar
• Grunwald V, Desar IM, Haanen J, et al. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). Acta Oncol. 2011;50:121–126.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Curti B, Ernstoff MS, et al. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014;2:2.
   PubMedGoogle Scholar
• Steele N, Anthony A, Saunders M, et al. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br J Cancer. 2012;106:793–798.
   PubMed Web of Science ®Google Scholar
• Montero J, Sarosiek KA, DeAngelo JD, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160:977–989.
   PubMed Web of Science ®Google Scholar